Recently, the Connecticut General Assembly’s Human Services Committee advanced SB 494, which proposes changes to the 340B Drug Pricing Program. Key provisions include requiring biopharmaceutical manufacturers to ship 340B drugs to all contract pharmacies and prohibiting manufacturers from collecting claims data linked to 340B pricing. Critics argue these changes will not reduce out-of-pocket costs for cancer patients and could diminish program transparency and oversight.
Historically designed to support safety net hospitals, the 340B program has seen revenue grow significantly, with little evidence that savings are directly benefiting uninsured or underinsured patients. Concerns have been raised about for-profit pharmacies profiting from these discounts, while hospitals may use 340B funds for margin improvements rather than patient care.
A bipartisan Prescription Drug Task Force report highlighted limited accountability in how 340B savings are utilized, suggesting they often do not directly subsidize patient care. With evidence of rising drug costs related to 340B, stakeholders argue for caution in expanding the program without tangible benefits to patients. Advocacy continues for improved oversight to ensure that those in need are supported effectively.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://ctmirror.org/2026/05/04/needy-ct-patients-wont-benefit-from-340b-changes/
